Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell — Stella

Home/Neoadjuvent/Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

View on ClinicalTrials.gov

Recruiting

Back to Neoadjuvent trials

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

Tangdu Hospital of the Fourth Millitary Medical University, Xi'an, Shaanxi

Hongtao Duan, Xi’an, Shanxi

Tangdu Hospital, the Air Force Military University, Xi'an

Key details

Phase

Safety & dosing

Sponsor

Tang-Du Hospital

Enrollment target

~114 participants

Started

August 2022

Primary completion

December 2031

Age range

18 Years – 75 Years

Last updated August 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.